10-K: Canton Strategic Pivots to Digital Assets, Secures $537M

Canton Strategic Holdings, Inc. has completed a major strategic shift from biotechnology to a digital asset treasury strategy focused on Canton Coin and the Canton Network, raising over $537 million in capital.

Summary

• Canton Strategic Holdings, Inc. (formerly Tharimmune, Inc.) has undergone a fundamental strategic shift, prioritizing digital asset treasury management and investment in the Canton Network, moving away from its primary focus on biotechnology operations.
• The company raised approximately $545 million in gross proceeds through a November 2025 private placement offering, consisting of a cash offering and a cryptocurrency pre-funded warrants offering.
• An additional $54.9 million in gross proceeds was raised through an underwritten registered direct offering in January 2026.
• The company's liquidity has significantly strengthened, alleviating previously disclosed substantial doubt about its ability to continue as a going concern, with sufficient liquidity projected through at least March 2027.
• Net loss for the year ended December 31, 2025, increased to $35.9 million from $12.2 million in 2024, primarily due to a $22.0 million unrealized loss from digital asset holdings.
• Research and development expenses decreased by $3.3 million (52%) to $3.1 million in 2025, while general and administrative expenses increased by $11.0 million (182%) to $17.0 million, reflecting the strategic shift and increased personnel costs.
• The company holds 3,339,567,946 Canton Coin (CC) units with a fair value of $501,760,369 as of December 31, 2025, and recognized a deferred tax liability of $117,934,191 related to these holdings.
• Key management changes include the appointment of Mark Wendland as CEO and Chairman, Mark Toomey as President, and Jacob Asbury as CFO, effective November and December 2025, respectively.
• The biotechnology segment continues to develop therapeutic candidates, with GV104 (for synthetic opioid exposure prophylaxis) anticipating a rolling NDA submission in H1 2027 and FDA approval in H1 2028, and GV023 (oral anti-TNF-alpha antibody) licensed from Intract Pharma Limited.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing with a moderately positive sentiment. While the significant capital raises and resolution of going concern issues are strong positives, the substantial unrealized loss on digital assets and the inherent volatility and regulatory risks of the new strategy introduce considerable uncertainty.

Positives

• Successfully raised over $537 million in net proceeds from a November 2025 private placement, significantly strengthening liquidity.
• Secured an additional $54.9 million in gross proceeds from a January 2026 registered direct offering, further bolstering capital position.
• Resolved previously identified substantial doubt about the company's ability to continue as a going concern, with sufficient liquidity for operations through at least March 2027.
• Approved to operate as a Super Validator on the Canton Network, expected to earn recurring protocol-based validation rewards in Canton Coin (CC).
• GV104, a therapeutic candidate, confirmed no additional clinical trials are required for its NDA submission, with anticipated submission in H1 2027 and FDA approval in H1 2028.
• Established an At-The-Market (ATM) program with $300 million available for issuance, providing flexible access to capital.
• New leadership team (CEO, President, CFO) appointed with extensive experience in capital markets and digital assets, aligning with the new strategic direction.

Negatives

• Net loss significantly increased to $35.9 million in 2025 from $12.2 million in 2024.
• Incurred a substantial $22.0 million unrealized loss from digital asset holdings in 2025.
• General and administrative expenses increased by $11.0 million (182%) in 2025, reflecting higher personnel and public company costs.
• The strategic shift from biotechnology to digital assets represents a fundamental change in risk profile and may not be successful, potentially leading to loss of biotech revenue streams and investor uncertainty.
• The company's financial results and stock price are highly susceptible to the extreme volatility of Canton Coin (CC) prices.
• The concentration of CC ownership could increase the risk of malicious activity or attacks on the Canton Network.
• The company faces significant competition in the digital asset space from well-resourced entities, including other public companies with CC holdings and spot exchange-traded funds (ETPs).

Risks

• Shifting business strategy from biotechnology to a CC treasury strategy represents a fundamental change in risk profile and may not be successful, potentially leading to loss of revenue streams from biotechnology operations and residual liabilities from prior activities.
• Subject to evolving regulatory developments related to crypto assets and crypto asset markets, which could adversely affect business, financial condition, and results of operations.
• Digital asset treasury exposure to CC involves novel and significant risks, including market volatility, accounting, regulatory, custody, cybersecurity, liquidity, and reputational risks.
• Failure of the Canton Network to achieve broad market acceptance would materially and adversely affect business, financial condition, and results of operations.
• Regulatory change reclassifying CC as a security could lead to classification as an investment company under the Investment Company Act of 1940, imposing additional regulatory controls and potentially forcing sales of CC at unattractive prices.
• Financial results and the market price of common stock may be significantly affected by the volatile prices of CC.
• Concentration of CC ownership could increase the risk of malicious activity, including potential attacks on the Canton Network, or influence over pricing inputs for transaction settlement.
• Risks relating to the custody of CC tokens, including loss or destruction of private keys, cyberattacks, smart contract vulnerabilities, and potential treatment as a general unsecured creditor in custodian insolvency.
• Operating in a highly competitive environment against companies and entities with similar digital asset strategies, including those with significant CC holdings and spot ETPs for digital assets.
• Availability of spot ETPs for CC and other digital assets may adversely affect the market price of listed securities by offering alternative investment exposure.
• If third-party service providers experience a security breach or cyberattack, or if private keys are lost or destroyed, some or all CC tokens may be lost.
• Exposure to the default risk of clearing brokers if derivative instruments are used to hedge CC price risk.
• Future developments regarding the treatment of crypto assets for U.S. and foreign tax purposes could adversely impact the business, including new or increased taxes or reporting requirements.
• Substantial dependence on the success of product candidates in the biotechnology segment; failure to complete development, obtain approval, or successfully commercialize could harm the business.
• Therapeutic candidate pipeline is based on novel, unproven ideas and technologies, making development timelines, costs, and regulatory approval difficult to predict.
• Delays, suspension, or termination of clinical trials could limit the ability to commercialize products and affect business prospects, including reliance on CROs and potential conflicts of interest.
• Outcome of pre-clinical testing and early clinical trials may not be predictive of later success, and interim data may change.
• Adverse side effects or safety risks could delay or preclude approval, cause suspension of clinical trials, or result in negative consequences following marketing approval.
• May not achieve development milestones on projected timelines, impacting commercialization and stock price.
• Product liability claims could materially harm the business, especially without adequate insurance coverage.
• Current and future products may never achieve significant commercial market acceptance due to various factors including clinical utility, regulatory clearance, reimbursement, and competition.
• Significant competition from companies developing more effective, safer, or less expensive products in the biotechnology and pharmaceutical industries.
• Subject to extensive healthcare laws and regulations, with potential for substantial financial penalties or business disruption for non-compliance.
• May not be able to obtain or maintain Fast Track, accelerated approval, or orphan drug designation/exclusivity for drug candidates.
• Reliance on third-party manufacturers for drug candidates exposes the company to risks related to insufficient supply, inadequate quality, and unfavorable cost structures.
• Dependence on sole source suppliers for active ingredients in product candidates could harm the business if supply is interrupted.
• Failure to find third-party collaborators for drug development could materially harm business, financial condition, and results of operations.
• Extensive regulation of pharmaceutical product development and commercialization by the FDA and other regulatory agencies, with unpredictable approval timelines and potential post-marketing requirements.
• Failure to obtain marketing approval in foreign jurisdictions would prevent drug candidates from being marketed abroad.
• Inability to develop satisfactory sales and marketing capabilities could hinder commercialization success.
• Unstable market and economic conditions and adverse developments with respect to financial institutions and associated liquidity risk may have serious adverse consequences on business, financial condition, and stock price.
• Changes to patent laws in the United States and other jurisdictions could diminish the value of patents, impairing the ability to protect drugs.
• Involvement in lawsuits to protect or enforce patent or other intellectual property rights could be expensive, time-consuming, and unsuccessful.
• Third parties may initiate legal proceedings alleging infringement of their intellectual property rights, which could have a material adverse effect on business success.
• Failure to comply with obligations in license arrangements with third parties could result in loss of important business rights.
• Inability to obtain licenses from third parties on commercially reasonable terms or at all could harm the business.
• Inability to protect intellectual property and proprietary rights in foreign jurisdictions where enforcement may be weaker.
• The price of the company's stock may be volatile, and investors could lose all or part of their investment.
• Sales of common stock, or the perception of such sales, could cause the market price of common stock to fall, leading to dilution.
• The company does not intend to pay dividends on common stock, limiting returns to stock value appreciation.
• Certificate of Incorporation provides that the Court of Chancery of the State of Delaware is the sole and exclusive forum for substantially all disputes, potentially limiting stockholders' ability to obtain a favorable judicial forum.
• Certificate of Incorporation, Bylaws, and Delaware law may have anti-takeover effects that could discourage, delay, or prevent a change in control.
• As an emerging growth company, reduced reporting requirements may make common stock less attractive to investors.
• Financial reporting obligations of being a public company are expensive and time-consuming, diverting management's attention.
• Failure to maintain an effective system of internal controls could lead to inaccurate financial results or fraud.
• If securities or industry analysts do not publish research or publish unfavorable reports, stock price and trading volume may decline.
• Could be subject to securities class action litigation, resulting in substantial costs and diversion of management's attention.

Future Outlook

The company intends to continue its digital asset treasury strategy, focusing on acquiring, holding, and deploying Canton Coin (CC) and supporting the Canton Network through validator operations, application support, and ecosystem participation. It plans to access capital markets for additional CC acquisitions and Canton-related ecosystem investments. In its biotechnology segment, the company anticipates initiating a rolling NDA submission for GV104 in the first half of 2027, with FDA approval expected in the first half of 2028. The company expects general and administrative expenses to increase due to personnel headcount and public company costs, while research and development expenses are projected to increase with planned clinical trials for HS3215 and HS1940.

Management Comments

• We are the first publicly traded company to leverage Canton Coin (CC) and support the Canton Network to advance institutional blockchain adoption and the digitization of financial markets.
• Our strategic digital asset reserve of CC reflects our conviction in the potential of the Canton Network to drive efficiency, transparency, and resiliency in global markets.
• This Canton digital asset treasury strategy is part of our broader approach to enhancing our platform with capital efficiency, diversifying treasury management practices, and engaging with emerging financial technologies.
• We believe championing broad-based participation will enhance the use case for Canton Network infrastructure and workflows, including custody, asset issuance, settlement, collateral and margin management, payments, and the integration of public and private market interfaces.
• Our board of directors retains broad discretion over investment, treasury, validator, and leverage policies and may amend or modify the digital assets treasury strategy.
• The Company intends to maintain internal controls, custody arrangements, risk limits, and compliance protocols designed to support the prudent execution of its strategy.
• Over time, participation in the Canton Network—through infrastructure operations, token management, and strategic ecosystem investments—may offer strategic advantages for product development and global expansion.

Industry Context

StockSavvy.ai notes that Canton Strategic's pivot to a digital asset treasury strategy positions it uniquely at the intersection of traditional finance and emerging blockchain technology. The focus on Canton Network, a public, permissionless blockchain with configurable privacy built for institutional scale, aims to capitalize on the growing trend of tokenized real-world assets and atomic settlement in global finance. This move places Canton Strategic in direct competition with specialized digital asset treasury companies, tokenization platforms, and digital asset investment vehicles, many of which possess greater financial resources and established market presence. The company's continued, albeit deprioritized, biotechnology operations provide a diversified, albeit smaller, exposure to the rapidly evolving pharmaceutical and biotech industries, characterized by intense competition and high R&D costs. The success of this dual strategy hinges on the widespread institutional adoption of the Canton Network and effective management of the inherent volatility and regulatory uncertainties of digital assets, while also navigating the complex and costly path of biopharmaceutical development.

Comparison to Industry Standards

• The company's strategic shift to a digital asset treasury model, particularly with a focus on a specific utility token like Canton Coin (CC), is a novel approach compared to traditional corporate treasury management, which typically prioritizes stable, liquid assets.
• Unlike established digital asset investment vehicles such as spot Bitcoin or Ethereum ETPs (e.g., BlackRock's IBIT or Grayscale's ETHE), Canton Strategic is an operating company that directly holds CC and participates in network validation, offering a different risk/reward profile.
• In the biotechnology sector, the pursuit of FDA 505(b)(2) regulatory pathway for GV104 is a common strategy for drug candidates with existing safety and effectiveness data, potentially accelerating approval compared to a full 505(b)(1) pathway, which is standard for new chemical entities.
• The company's accumulated deficit of $72.8 million as of December 31, 2025, and recurring operating losses are typical for clinical-stage biotechnology companies, which often incur significant R&D expenses without generating revenue for extended periods, but the magnitude of the unrealized loss from digital assets is specific to its new strategy.
• The capital raises of over $537 million in late 2025 and early 2026 are substantial for a company of this size, providing a strong liquidity position that contrasts with many smaller biotech firms that frequently face going concern issues.

Management Changes

Corporate Governance

Legal Proceedings

• Currently not aware of any legal proceedings or claims that will have, individually or in the aggregate, a material adverse effect on the business, financial condition or operating results.

Related Party Transactions

• The company's Chairman (through year ended December 31, 2025) is a partner and licensed broker at President Street Global, a consultant for the company, and holds approximately 4% of outstanding common stock.
• During 2025, the Chairman purchased 337,338 common shares, Series A Warrants, and Series B Warrants in the June 2025 PIPE Offering for $500,000.
• Payments of approximately $3.5 million were made to President Street Global for services rendered in 2025, including offering commissions.
• President Street Global received placement agent warrants to purchase up to 326,750 shares of common stock as compensation for various PIPE offerings.
• The CEO of Gravitas (formerly COO of the company) owns less than 1% of outstanding common stock and purchased 60,806 common shares, Series A Warrants, and Series B Warrants in the June 2025 PIPE Offering.
• A $50,000 contribution was made to a not-for-profit organization where the co-founder and president is a former board member.
• The company purchased $77,572,536 of Canton Coin (CC) in OTC transactions from an affiliate cryptocurrency liquidity provider controlled by a >5% shareholder.

Stakeholder Impact

• **Shareholders:** Significant dilution from recent and planned equity issuances (warrants, ATM program) and potential future capital raises. The strategic shift to digital assets introduces high volatility and regulatory risks, potentially impacting stock price. However, the resolution of going concern doubts and substantial capital infusion provide financial stability.
• **Employees:** Management changes reflect the strategic pivot, with new leadership in key executive roles. Equity incentive plans aim to attract and retain talent, but the shift in focus may alter career paths for those in the biotechnology segment.
• **Customers (Biotech):** Development of therapeutic candidates like GV104 and GV023 continues, aiming to address unmet medical needs in inflammatory and immunologic conditions. Delays or failures in clinical trials could impact future patient access to these therapies.
• **Suppliers/Partners:** Reliance on third-party manufacturers and CROs for biotech operations continues, with potential risks if these partners fail to deliver. The digital asset strategy involves new third-party service providers (custodians, trading venues), introducing new counterparty and operational risks.
• **Creditors:** The substantial capital raises have significantly improved the company's liquidity and financial position, reducing immediate credit risk and alleviating going concern concerns.

Next Steps

• Operate as a Super Validator and run additional validator nodes on the Canton Network to earn recurring protocol-based validation rewards.
• Build, sponsor, or invest in applications and middleware that complement capital markets transactions on the Canton Network.
• Collaborate with other Super Validators and ecosystem participants to enhance Canton Network use cases.
• Access capital markets through the ATM program and other offerings to acquire additional CC and make Canton-related ecosystem investments.
• Deploy a portion of CC holdings into long-term locking programs, engage in CC lending, and utilize CC-linked options and derivatives.
• Continue to shape the Canton Network's governance framework, tokenomics, and strategic roadmap through participation in the Canton Foundation.
• Progress the Chemistry, Manufacturing, and Controls (CMC) plan for GV104 to meet NDA filing requirements.
• Initiate a rolling NDA submission for GV104 in the first half of 2027.
• Seek FDA approval for GV104 in the first half of 2028.
• Pursue the pruritus in PBC indication for GV104 subsequent to the PrHPO NDA filing.
• Plan for and commence clinical trials of HS3215 and HS1940.
• Increase personnel headcount to support the digital asset treasury strategy and continued research activities.

Key Dates

Recommendation

The company has undergone a significant strategic pivot to digital assets, which introduces both substantial opportunity and high risk. While the recent capital raises have addressed immediate liquidity concerns and the company is actively pursuing its new digital asset treasury strategy, the inherent volatility of Canton Coin (CC) and the evolving regulatory landscape for cryptocurrencies create considerable uncertainty. The large unrealized loss on digital assets in 2025 highlights this risk. For a seasoned investor, a 'hold' recommendation is appropriate to observe the execution of the new strategy, the performance of the digital asset holdings, and the impact of regulatory developments before making a more definitive investment decision. The biotech pipeline, while still active, is deprioritized and its future contribution to value is less clear in the context of the new primary focus.

Keywords

Canton Coin, Digital Asset Treasury, Canton Network, Blockchain, Cryptocurrency, Biotechnology, SEC Filing, 10-K, Financial Markets, Institutional Adoption, Validator Operations, GV104, GV023, Clinical Trials, Nalmefene, Infliximab, Strategic Shift, Capital Raise, Market Volatility, Regulatory Risk, Corporate Governance, Nasdaq